Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study to Assess the Safety, Tolerability, Biodistribution and Pharmacodynamic of T3011 Herpes Virus Administered Via Intravenously in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase I/IIa Study to Assess the Safety, Tolerability, Biodistribution and Pharmacodynamic of T3011 Herpes Virus Administered Via Intravenously in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs T 3011 (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Immvira Pharma

    • Most Recent Events

    • 06 Jun 2023 Results (N=15, cut off date :16 Dec 2022) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2023 According to an Immvira Pharma media release, MVR-T3011 IV's U.S. Phase I clinical data was also selected to be published at ASCO this year. We are expecting to report more intravenous clinical results in both U.S. and China in the future.
    • 06 Jun 2023 According to an Immvira Pharma media release, the company has presented results from this trial of MVR-T3011 IV, global first intravenous oHSV product, showed assuring safety profile with all selected to be published (1 chosen for poster discussion) at the 2023 American Society for Clinical Oncology Annual Meeting (ASCO 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top